To CRISPR and beyond: The evolution of genome editing in stem cells

Kuang Yui Chen, Paul S Knoepfler

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The goal of editing the genomes of stem cells to generate model organisms and cell lines for genetic and biological studies has been pursued for decades. There is also exciting potential for future clinical impact in humans. While recent, rapid advances in targeted nuclease technologies have led to unprecedented accessibility and ease of gene editing, biology has benefited from past directed gene modification via homologous recombination, gene traps and other transgenic methodologies. Here we review the history of genome editing in stem cells (including via zinc finger nucleases, transcription activator-like effector nucleases and CRISPR-Cas9), discuss recent developments leading to the implementation of stem cell gene therapies in clinical trials and consider the prospects for future advances in this rapidly evolving field.

Original languageEnglish (US)
Pages (from-to)801-816
Number of pages16
JournalRegenerative Medicine
Volume11
Issue number8
DOIs
StatePublished - Dec 1 2016

Fingerprint

Clustered Regularly Interspaced Short Palindromic Repeats
Stem cells
Stem Cells
Genes
Homologous Recombination
Zinc Fingers
Cell- and Tissue-Based Therapy
Genetic Therapy
Gene therapy
History
Clinical Trials
Technology
Cell Line
Transcription
Zinc
Cells
Gene Editing

Keywords

  • CRISPR-Cas9
  • gene therapy
  • genome editing
  • stem cells
  • TALEN
  • ZFN

ASJC Scopus subject areas

  • Embryology
  • Biomedical Engineering

Cite this

To CRISPR and beyond : The evolution of genome editing in stem cells. / Chen, Kuang Yui; Knoepfler, Paul S.

In: Regenerative Medicine, Vol. 11, No. 8, 01.12.2016, p. 801-816.

Research output: Contribution to journalReview article

@article{120f836356484309b67990928457d5ba,
title = "To CRISPR and beyond: The evolution of genome editing in stem cells",
abstract = "The goal of editing the genomes of stem cells to generate model organisms and cell lines for genetic and biological studies has been pursued for decades. There is also exciting potential for future clinical impact in humans. While recent, rapid advances in targeted nuclease technologies have led to unprecedented accessibility and ease of gene editing, biology has benefited from past directed gene modification via homologous recombination, gene traps and other transgenic methodologies. Here we review the history of genome editing in stem cells (including via zinc finger nucleases, transcription activator-like effector nucleases and CRISPR-Cas9), discuss recent developments leading to the implementation of stem cell gene therapies in clinical trials and consider the prospects for future advances in this rapidly evolving field.",
keywords = "CRISPR-Cas9, gene therapy, genome editing, stem cells, TALEN, ZFN",
author = "Chen, {Kuang Yui} and Knoepfler, {Paul S}",
year = "2016",
month = "12",
day = "1",
doi = "10.2217/rme-2016-0107",
language = "English (US)",
volume = "11",
pages = "801--816",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd.",
number = "8",

}

TY - JOUR

T1 - To CRISPR and beyond

T2 - The evolution of genome editing in stem cells

AU - Chen, Kuang Yui

AU - Knoepfler, Paul S

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The goal of editing the genomes of stem cells to generate model organisms and cell lines for genetic and biological studies has been pursued for decades. There is also exciting potential for future clinical impact in humans. While recent, rapid advances in targeted nuclease technologies have led to unprecedented accessibility and ease of gene editing, biology has benefited from past directed gene modification via homologous recombination, gene traps and other transgenic methodologies. Here we review the history of genome editing in stem cells (including via zinc finger nucleases, transcription activator-like effector nucleases and CRISPR-Cas9), discuss recent developments leading to the implementation of stem cell gene therapies in clinical trials and consider the prospects for future advances in this rapidly evolving field.

AB - The goal of editing the genomes of stem cells to generate model organisms and cell lines for genetic and biological studies has been pursued for decades. There is also exciting potential for future clinical impact in humans. While recent, rapid advances in targeted nuclease technologies have led to unprecedented accessibility and ease of gene editing, biology has benefited from past directed gene modification via homologous recombination, gene traps and other transgenic methodologies. Here we review the history of genome editing in stem cells (including via zinc finger nucleases, transcription activator-like effector nucleases and CRISPR-Cas9), discuss recent developments leading to the implementation of stem cell gene therapies in clinical trials and consider the prospects for future advances in this rapidly evolving field.

KW - CRISPR-Cas9

KW - gene therapy

KW - genome editing

KW - stem cells

KW - TALEN

KW - ZFN

UR - http://www.scopus.com/inward/record.url?scp=85002427088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002427088&partnerID=8YFLogxK

U2 - 10.2217/rme-2016-0107

DO - 10.2217/rme-2016-0107

M3 - Review article

C2 - 27905217

AN - SCOPUS:85002427088

VL - 11

SP - 801

EP - 816

JO - Regenerative Medicine

JF - Regenerative Medicine

SN - 1746-0751

IS - 8

ER -